Opendata, web and dolomites

NEFERTITI SIGNED

A Novel Eco-Friendly, dually Efficient and Resistance-free Treatment of vaginITIs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEFERTITI project word cloud

Explore the words cloud of the NEFERTITI project. It provides you a very rough idea of what is the project "NEFERTITI" about.

clinical    antifungals    repeatedly    restores    recur    heavy    commercialised    recurrence    plan    bacterial    physical    combination    aerobic    trademarked    fti    pathogenic    candida    lactone    adversely    bv    treat    unmatched    drug    infected    leads    opt    business    commercial    resistance    encountering    mucosa    natural    cure    distributor    trigger    acute    delta    discomfort    antibiotics    infections    rapid    socioeconomic    vulvovaginal    misuse    prescription    solution    microbiome    prescribed    phyph    market    counter    overconsumption    self    form    properly    causative    treatments    levels    trials    women    vvc    7bn    proliferation    single    candidiasis    biofilms    caused    worth    2024    disrupts    infection    pessary    rates    gardnerella    commercialisation    68m    course    mark    intense    fail    vcc    post    regulatory    displaces    fungi    recurrent    lactobacilli    alternative    life    nefertiti    efficacy    protective    vaginal    anaerobic    compliance    quality    promotes    misdiagnosis    2022    glucono    curative    once    microorganism    pathogens    bacteria    ph4    vaginosis   

Project "NEFERTITI" data sheet

The following table provides information about the project.

Coordinator
GEDEA BIOTECH AB 

Organization address
address: MEDICON VILLAGE SCHEELEVAGEN 2
city: LUND
postcode: 223 81
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 4˙186˙716 €
 EC max contribution 2˙991˙774 € (71%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GEDEA BIOTECH AB SE (LUND) coordinator 1˙970˙073.00
2    LINK MEDICAL RESEARCH AS NO (OSLO) participant 818˙125.00
3    NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST UK (Nottingham) participant 203˙576.00

Map

 Project objective

Bacterial vaginosis (BV) and vulvovaginal candidiasis (VCC) are common vaginal infections caused by Gardnerella and other anaerobic bacteria. or by Candida fungi. The infection can occur once - the acute form - or recur repeatedly over the course of a year. About 68m women in Europe and the US are infected each year. They cause intense physical discomfort, adversely affects quality of life and have heavy socioeconomic costs.

Many women opt to self-treat with non-prescription over-the-counter antifungals which fail because the causative microorganism has not been properly identified. Antibiotics for BV are encountering increasing levels of drug resistance. Combination of misdiagnosis, misuse, non-compliance, overconsumption leads to low efficacy and high recurrence rates for both VVC and BV.

NEFERTITI FTI will demonstrate in clinical trials a pessary based on glucono-δ-lactone –trademarked as pHyph - as a highly effective cure for acute and recurrent BV and VVC, and as a far better alternative to antibiotics or antifungals. pHyph restores the vaginal mucosa to pH4 and disrupts Candida biofilms, promotes the proliferation of natural and protective aerobic lactobacilli, and displaces Gardnerella and other anaerobic pathogenic bacteria. pHyph is a single solution for both pathogens and infections, and with both curative and protective effects, and does not trigger drug resistance in the microbiome. These features are unmatched by any other product on the market – whether as over the counter or prescribed.

NEFERTITI FTI will also develop a post-project business plan for the rapid scale up of production and commercialisation of pHyph in Europe in 2022 as an over-the-counter product into a market for BV and VVC treatments worth €1.7bn in 2022 and will be commercialised through a major drug distributor. The same plan will also mark the regulatory steps and commercial partners needed for pHyph to reach the US market in 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEFERTITI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEFERTITI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

Read More  

De-RISC (2019)

De-RISC: Dependable Real-time Infrastructure for Safety-critical Computer

Read More  

SAMBAfun (2018)

System for AcceleroMeter-Based Assessment of cardiac FUNction

Read More